PMID: 11907174Mar 22, 2002Paper

Differential effects of haloperidol and clozapine on [(3)H]cAMP binding, protein kinase A (PKA) activity, and mRNA and protein expression of selective regulatory and catalytic subunit isoforms of PKA in rat brain

The Journal of Pharmacology and Experimental Therapeutics
Yogesh DwivediGhanshyam N Pandey

Abstract

The present study was undertaken to examine whether the mechanism of action of typical and atypical antipsychotics is related in their ability to regulate key phosphorylating enzyme of adenylyl cyclase-cAMP pathway, i.e., protein kinase A (PKA). For this purpose, regulatory (R) and catalytic (Cat) activities of PKA and expression of various isoforms of regulatory and catalytic subunits were examined in rat brain after single or chronic (21-day) treatment with haloperidol (HAL, 1 mg/kg) or clozapine (CLOZ, 20 mg/kg). It was observed that chronic but not acute treatment of CLOZ significantly decreased [(3)H]cAMP binding to the regulatory subunit of PKA as well as catalytic activity of PKA in particulate and cytosol fractions of the rat cortex, hippocampus, and striatum. In these fractions, CLOZ significantly decreased protein levels of selective RII alpha-, RII beta-, and Cat beta-subunit isoforms of PKA. These decreases were accompanied by decreases in their respective mRNA expression. In contrast, chronic but not acute treatment of HAL significantly increased [(3)H]cAMP binding and the catalytic activity of PKA in particulate and cytosol fractions of only the striatum brain area. In addition, chronic treatment of HAL significan...Continue Reading

References

May 1, 1992·Prostaglandins, Leukotrienes, and Essential Fatty Acids·M KanekoH Kumashiro
Jan 1, 1992·Journal of Molecular Neuroscience : MN·S K Gupta, R K Mishra
Jan 1, 1992·The British Journal of Psychiatry : the Journal of Mental Science·P McGuffin, A Thapar
Feb 25, 1992·European Journal of Pharmacology·H KanedaC A Tamminga
Jan 1, 1991·Schizophrenia Bulletin·A SaffermanB Kinon
Jan 1, 1990·European Neurology·R K PearceW W Tourtellotte
Aug 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·J D ScottE G Krebs
Oct 1, 1988·Acta Neurologica Scandinavica·K Ostergaard, E Dupont
Mar 1, 1986·Acta Neurologica Scandinavica·H Pakkenberg, B Pakkenberg
Nov 1, 1985·Journal of Pharmacological Methods·G A McPherson
Oct 14, 1994·European Journal of Pharmacology·M KuoppamäkiJ Hietala
Jul 1, 1993·Movement Disorders : Official Journal of the Movement Disorder Society·G J Arevalo, O S Gershanik
Aug 1, 1993·Brain Research. Molecular Brain Research·R E SeeP W Kalivas
Jan 1, 1995·Schizophrenia Bulletin·L B DixonJ Levine
Mar 5, 1997·European Journal of Pharmacology·X P ZengE Richelson
Jul 1, 1997·Frontiers in Bioscience : a Journal and Virtual Library·B S Skålhegg, K Taskén
Jul 7, 2000·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·D TarditoJ Perez

❮ Previous
Next ❯

Citations

Mar 12, 2009·Journal of Molecular Neuroscience : MN·Avril PereiraSuresh Sundram
Oct 6, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Agnieszka Basta-KaimWładysław Lasoń
Jun 2, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Michele P KellyTed Abel
Jan 8, 2008·The Journal of Pharmacology and Experimental Therapeutics·Mohamed Rafiuddin AhmedEugenia V Gurevich
May 12, 2009·Psychiatry Research·Giuseppe BlasiAlessandro Bertolino
Jun 29, 2004·Biological Psychiatry·Yogesh DwivediJennifer Lyons
Sep 6, 2014·Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology·Myoung Suk SeoBrian Dean
Dec 15, 2005·Toxicology and Applied Pharmacology·Juan A OrellanaJuan C Sáez
Jan 5, 2005·Biochemical and Biophysical Research Communications·Kazunori KashiwaseKinya Otsu
Jun 23, 2009·Pharmacology & Therapeutics·Raffaella MolteniMarco Andrea Riva
Jul 24, 2013·Journal of Genetics and Genomics = Yi Chuan Xue Bao·Feng LiShimin Zhao
Sep 14, 2010·Best Practice & Research. Clinical Endocrinology & Metabolism·Anya Rothenbuhler, Constantine A Stratakis
Feb 26, 2014·Journal of Psychiatric Research·Ghanshyam N PandeyYogesh Dwivedi
May 13, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Kerry E CulmRonald P Hammer
Nov 30, 2016·Translational Psychiatry·E KristófL Fésüs
Mar 29, 2011·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Gianluca SerafiniYogesh Dwivedi
May 22, 2009·Journal of Neurochemistry·Jana Sánchez-WandelmerRebeca Busto
Mar 8, 2008·The Journal of Biological Chemistry·Martha Zentella de PiñaEnrique Piña
Oct 17, 2008·Pharmacological Reviews·Jeffrey A LiebermanJohn G Csernansky
Nov 1, 2003·The Journal of Pharmacology and Experimental Therapeutics·Kerry E Culm, Ronald P Hammer
May 31, 2021·Biochemical Pharmacology·Miguel A LasunciónDiego Gómez-Coronado
Sep 8, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Yogesh Dwivedi, Ghanshyam N Pandey

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here